Dataset Information

Longitudinal change of FEV₁ and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD.

ABSTRACT:

Background and objective

FEV₁ is the gold standard for assessment of COPD. We compared efficacy of FEV₁, inspiratory capacity (IC), and IC to total lung capacity (TLC) ratio in the evaluation of COPD and their association with exacerbation.

Methods

We analyzed the association of dyspnea severity, quality of life status, and lung function with lung function measurements and exacerbation risk in 982 patients enrolled in the Korea COPD Subgroup Registry and Subtype Research study. Exacerbation and longitudinal lung function change were evaluated in 3 years' follow-up.

Results

The FEV₁, IC, and IC to TLC ratio showed comparable negative correlations with dyspnea severity and quality of life status, and positive correlation with exercise capacity. In patients with >2 events/year, annual rate of change in FEV₁ and IC tended to decline more rapidly in those with FEV₁ <50% than in those with FEV₁ >50% (-14.46±19.40 mL/year vs 12.29±9.24 mL/year, P=0.213; -4.75±17.28 mL/year vs -78.05±34.16 mL/year, P=0.056 for FEV₁ and IC, respectively), without significance.

Conclusion

Longitudinal changes in IC and FEV₁ were not significantly associated with exacerbation risk.

SUBMITTER: Jo YS

PROVIDER: S-EPMC6366360 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Longitudinal change of FEV<sub>1</sub> and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD.

Jo Yong Suk YS Kim Sung Kyoung SK Park Seoung Ju SJ Um Soo-Jung SJ Park Yong-Bum YB Jung Ki Suck KS Kim Deog Kyeom DK Yoo Kwang Ha KH

International journal of chronic obstructive pulmonary disease 20190204

<h4>Background and objective</h4>FEV<sub>1</sub> is the gold standard for assessment of COPD. We compared efficacy of FEV<sub>1</sub>, inspiratory capacity (IC), and IC to total lung capacity (TLC) ratio in the evaluation of COPD and their association with exacerbation.<h4>Methods</h4>We analyzed the association of dyspnea severity, quality of life status, and lung function with lung function measurements and exacerbation risk in 982 patients enrolled in the Korea COPD Subgroup Registry and Subt ...[more]

PMID: 30787605

Similar Datasets

Project description:BackgroundSmall airways are known to be affected early in the course of COPD; however, traditional spirometric indices may not accurately identify small airways disease.Research questionCan forced expiratory volume in 3 s/forced expiratory volume in 6 s (FEV3/FEV6) identify early airflow abnormalities and predict future clinically important respiratory-related outcomes, including development of COPD?Study design and methodsThe study included 832 current and former smokers with post-bronchodilator FEV1/FVC ≥ 0.7 from the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) cohort. Participants were classified as having a reduced pre-bronchodilator FEV3/FEV6 based on lower limit of normal (LLN) values. Repeatability analysis was performed for FEV3 and FEV6. Regression modeling was used to evaluate the relationship between baseline FEV3/FEV6 and outcome measures, including functional small airways disease, on thoracic imaging and respiratory exacerbations. Interval-censored analysis was used to assess progression to COPD.ResultsFEV3/FEV6 less than the LLN at baseline, defined as reduced compared with FEV3/FEV6 at or above the LLN, was associated with lower FEV1, poorer health status (St. George's Respiratory Questionnaire score), more emphysema, and more functional small airways disease on quantitative imaging. FEV3 and FEV6 showed excellent agreement between repeat measurements. A reduced FEV3/FEV6 was associated with increased odds of a severe respiratory exacerbation within the first year of follow-up and decreased time to first exacerbation. A low FEV3/FEV6 was also associated with development of COPD according to spirometry results (post-bronchodilator FEV1/FVC < 0.7) during study follow-up.InterpretationFEV3/FEV6 is a routinely available and repeatable spirometric index that can be useful in the evaluation of early airflow obstruction in current and former smokers without COPD. A reduced FEV3/FEV6 can identify those at risk for future development of COPD and respiratory exacerbations.Clinical trial registrationClinicalTrials.gov; No.: NCT01969344; URL: www.Clinicaltrialsgov: ClinicalTrials.gov.

Dataset Information

Longitudinal change of FEV₁ and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD.

Background and objective

Methods

Results

Conclusion

Publications

Longitudinal change of FEV<sub>1</sub> and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Longitudinal change of FEV1 and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD.

Background and objective

Methods

Results

Conclusion

Publications

Longitudinal change of FEV<sub>1</sub> and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Longitudinal change of FEV₁ and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD.